Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

2(50.0%)

N/A

1(25.0%)

Phase 1

1(25.0%)

4Total

Phase 2(2)

N/A(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04055454Phase 1Completed

A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)

Role: collaborator

NCT06779981Completed

A Prospective Epidemiological Study Evaluating Occurrences of Influenza-like Illness

Role: collaborator

NCT06582277Phase 2Completed

Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836

Role: collaborator

NCT05284799Phase 2Completed

Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.

Role: collaborator

NCT03188302Not ApplicableCompleted

Evaluation of New Method for Measuring Stool Consistency

Role: collaborator

All 5 trials loaded